激动剂-话题@MedSci

#激动剂#

173篇内容 | 3637人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1627726, encodeId=264b162e726af, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet Respir Med：β2受体激动剂引起的支气管收缩效应, objectType=article, longId=44787, objectId=1e7544e8722, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e7544e8722, replyNumber=0, likeNumber=52, createdTime=2014-12-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e7544e8722, moduleTitle=Lancet Respir Med：β2受体激动剂引起的支气管收缩效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e7544e8722)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627725, encodeId=24e3162e72599, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA Int Med：阿片受体激动剂的维持疗法或可降低注射吸毒者感染丙肝的发生率, objectType=article, longId=41940, objectId=40374194024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40374194024, replyNumber=0, likeNumber=63, createdTime=2014-11-01, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40374194024, moduleTitle=JAMA Int Med：阿片受体激动剂的维持疗法或可降低注射吸毒者感染丙肝的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40374194024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627724, encodeId=990a162e72462, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Nat Commun：Bax激动剂有望成为新一代肺癌治疗新药, objectType=article, longId=41890, objectId=5ada41890a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ada41890a4, replyNumber=0, likeNumber=77, createdTime=2014-10-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ada41890a4, moduleTitle=Nat Commun：Bax激动剂有望成为新一代肺癌治疗新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ada41890a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes Care：GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗, objectType=article, longId=36769, objectId=f77936e69cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f77936e69cd, replyNumber=0, likeNumber=61, createdTime=2014-06-21, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f77936e69cd, moduleTitle=Diabetes Care：GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f77936e69cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627722, encodeId=9629162e722b4, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Circulation：新型降糖药胰高血糖素样肽-1受体激动剂的心脏保护作用, objectType=article, longId=36241, objectId=feee36241f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feee36241f3, replyNumber=0, likeNumber=92, createdTime=2014-06-12, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feee36241f3, moduleTitle=Circulation：新型降糖药胰高血糖素样肽-1受体激动剂的心脏保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feee36241f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627721, encodeId=7851162e72118, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA Psychiatry：褪黑素受体激动剂Ramelteon 或可预防ICU和急诊患者谵妄发生（DELIRIA-J研究）, objectType=article, longId=34013, objectId=76373401341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76373401341, replyNumber=0, likeNumber=82, createdTime=2014-05-03, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76373401341, moduleTitle=JAMA Psychiatry：褪黑素受体激动剂Ramelteon 或可预防ICU和急诊患者谵妄发生（DELIRIA-J研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76373401341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627720, encodeId=c89a162e720d5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=APT：慢性便秘患者更倾向高选择性5-HT4受体激动剂, objectType=article, longId=33666, objectId=0703336665e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0703336665e, replyNumber=0, likeNumber=84, createdTime=2014-04-24, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0703336665e, moduleTitle=APT：慢性便秘患者更倾向高选择性5-HT4受体激动剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0703336665e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627719, encodeId=86c0162e71953, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Sanofi推迟GLP-1受体激动剂lixisenatide在FDA的申请, objectType=article, longId=24431, objectId=a5022443132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5022443132, replyNumber=0, likeNumber=94, createdTime=2013-09-15, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5022443132, moduleTitle=Sanofi推迟GLP-1受体激动剂lixisenatide在FDA的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5022443132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627718, encodeId=c8e4162e71872, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=STM ：刺猬索尼克通路激动剂对抗唐氏综合症, objectType=article, longId=24070, objectId=da79240e0df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da79240e0df, replyNumber=0, likeNumber=64, createdTime=2013-09-11, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da79240e0df, moduleTitle=STM ：刺猬索尼克通路激动剂对抗唐氏综合症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da79240e0df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627717, encodeId=29d0162e71711, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=PUDF 2013：母义明-GLP-1受体激动剂，它们都一样吗？, objectType=article, longId=19468, objectId=1004194680a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1004194680a, replyNumber=0, likeNumber=87, createdTime=2013-06-01, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1004194680a, moduleTitle=PUDF 2013：母义明-GLP-1受体激动剂，它们都一样吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1004194680a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627716, encodeId=30b7162e71689, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Gastroenterology：黑猩猩试验表明TLR-7口服激动剂GS-9620或可治疗慢性乙型肝炎, objectType=article, longId=17888, objectId=17841e88817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17841e88817, replyNumber=0, likeNumber=68, createdTime=2013-05-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17841e88817, moduleTitle=Gastroenterology：黑猩猩试验表明TLR-7口服激动剂GS-9620或可治疗慢性乙型肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17841e88817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627715, encodeId=7d76162e71545, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA Pediatr:GLP-1受体激动剂抗青少年重度肥胖, objectType=article, longId=15216, objectId=a583152166d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a583152166d, replyNumber=0, likeNumber=71, createdTime=2013-02-19, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a583152166d, moduleTitle=JAMA Pediatr:GLP-1受体激动剂抗青少年重度肥胖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a583152166d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627714, encodeId=78c5162e714ff, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=欧盟评估左旋多巴、多巴胺激动剂冲动控制障碍风险, objectType=article, longId=11937, objectId=7d411193eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d411193eed, replyNumber=0, likeNumber=73, createdTime=2012-11-30, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d411193eed, moduleTitle=欧盟评估左旋多巴、多巴胺激动剂冲动控制障碍风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d411193eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627713, encodeId=5f7e162e713a7, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet：新药GPR40激动剂TAK-875可有效控制血糖, objectType=article, longId=4489, objectId=042244890b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=042244890b, replyNumber=0, likeNumber=75, createdTime=2012-04-02, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=042244890b, moduleTitle=Lancet：新药GPR40激动剂TAK-875可有效控制血糖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=042244890b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激动剂

2020-05-29

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet Respir Med：β2受体激动剂引起的支气管收缩效应

2014-12-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA Int Med：阿片受体激动剂的维持疗法或可降低注射吸毒者感染丙肝的发生率

2014-11-01

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Nat Commun：Bax激动剂有望成为新一代肺癌治疗新药

2014-10-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes Care：GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗

2014-06-21

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Circulation：新型降糖药胰高血糖素样肽-1受体激动剂的心脏保护作用

2014-06-12

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA Psychiatry：褪黑素受体激动剂Ramelteon 或可预防ICU和急诊患者谵妄发生（DELIRIA-J研究）

2014-05-03

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

APT：慢性便秘患者更倾向高选择性5-HT4受体激动剂

2014-04-24

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Sanofi推迟GLP-1受体激动剂lixisenatide在FDA的申请

2013-09-15

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

STM ：刺猬索尼克通路激动剂对抗唐氏综合症

2013-09-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

PUDF 2013：母义明-GLP-1受体激动剂，它们都一样吗？

2013-06-01

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Gastroenterology：黑猩猩试验表明TLR-7口服激动剂GS-9620或可治疗慢性乙型肝炎

2013-05-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA Pediatr:GLP-1受体激动剂抗青少年重度肥胖

2013-02-19

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

欧盟评估左旋多巴、多巴胺激动剂冲动控制障碍风险

2012-11-30

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet：新药GPR40激动剂TAK-875可有效控制血糖

2012-04-02

科室
- - 订阅+
  - 更多科室
工具
服务